KDUS

 
Common Stock SEC Reporting - Current
OTCQB
Contact Info
  • 767 Fifth Avenue
  • New York, NY 10153

Business Description


Update Company Profile
 
Financial Reporting/Disclosure
Reporting Status U.S. Reporting: SEC Reporting
Audited Financials Audited
Latest Report Sep 30, 2016 10-Q
CIK 0000911148
Fiscal Year End 12/31
OTC Marketplace OTCQB
Profile Data
SIC - Industry Classification 6500 - Real Estate
Incorporated In: DE, USA
Year of Inc. Not Available
Employees Not Available
Company Officers/Contacts
Hunter C. Gary President, CEO
David Blitz Treasurer, Secretary
Company Directors
Jack Wasserman Chairman
Hunter C. Gary
Peter Liebert
Tara Shucts
Service Providers
Accounting/Auditing Firm
Baker Tilly Virchow Krause
One Penn Plaza
Suite 3000
New York, NY, 10119
United States
 
Securities Counsel
Morrison Cohen LLP
909 Third Avenue
New York, NY, 10022-4784
United States
 
Investor Relations Firm

Not Available
Company History
  • Formerly=Cadus Pharmaceutical Corp. until 7-03
KDUS Security Details
Share Structure
Market Value1 $28,391,126 a/o Feb 17, 2017
Authorized Shares 35,000,000 a/o Dec 07, 2016
Outstanding Shares 26,288,080 a/o Mar 31, 2016
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float Not Available
Par Value 0.01
Shareholders
Shareholders of Record 46 a/o Mar 30, 2016
Short Selling Data
Short Interest 13,501 (-14.51%)
Jan 31, 2017
Significant Failures to Deliver No

1Market Value calculated only for respective security